Cannabinoid Encyclopedia

Focused research review

2-AG: what the research says

What evidence defines 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?

Updated July 2026 14 research sources Mostly early-stage research

The short answer

What is the bottom line?

Research has examined 2-AG. This page brings together 2 human-study sources, 8 research reviews, and 4 lab, animal, or mechanism sources. Most of the current evidence is preclinical or focused on biological mechanisms. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about 2-AG.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on 2-AG covers 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-releva...; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about 2-AG

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-releva...

This part of the literature focuses on 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-releva.... Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

2 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

8 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

4 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on 2-AG is not one kind of study. This source set includes 8 narrative or expert reviews and 5 animal studies. 3

The recorded populations or models include animal models (4 sources), people or patients (3 sources), and cells or tissue models (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms (14 sources). Closely related outcome names can still describe different measurements. 5

The 2-AG source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids.

On this page, this source examines 2-AG and 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. 1

Study type
narrative or expert review
Outcome focus
2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
evidence still limited

narrative or expert review

The Endocannabinoid System and its Modulation by Phytocannabinoids.

On this page, this source examines 2-AG and 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. 2

Study type
narrative or expert review
Outcome focus
2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
evidence still limited

animal study

Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.

On this page, this source examines 2-AG and 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. 3

Study type
animal study
Population or model
animal models
Outcome focus
2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
mechanism-focused research

animal study

A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.

On this page, this source examines 2-AG and 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. 4

Study type
animal study
Population or model
animal models
Outcome focus
2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
preclinical research

narrative or expert review

Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.

On this page, this source examines 2-AG and 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. 5

Study type
narrative or expert review
Population or model
animal models
Outcome focus
2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on 2-AG should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What evidence defines 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms?

Relevant research is collected here. Most of the current evidence is preclinical or focused on biological mechanisms. 7

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 8

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. narrative or expert review; evidence still limited PubMed 24676249 DOI 10.1039/c4cs00047a
  2. 2
    The Endocannabinoid System and its Modulation by Phytocannabinoids. narrative or expert review; evidence still limited PubMed 26271952 DOI 10.1007/s13311-015-0374-6
  3. 3
    Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. animal study; mechanism-focused research PubMed 39612328 DOI 10.1126/sciadv.adq4779
  4. 4
    A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence. animal study; preclinical research PubMed 38052772 DOI 10.1038/s41467-023-43606-3
  5. 5
    Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. narrative or expert review; evidence still limited PubMed 16678907 DOI 10.1016/j.plipres.2006.03.003
  6. 6
    Cannabinergic ligands. narrative or expert review; evidence still limited PubMed 12505686 DOI 10.1016/s0009-3084(02
  7. 7
    Endocannabinoid hydrolases. narrative or expert review; evidence still limited PubMed 12432941 DOI 10.1016/s0090-6980(02
  8. 8
    Endocannabinoid overload. narrative or expert review; evidence still limited PubMed 20952498 DOI 10.1124/mol.110.069427
  9. 9
    Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. narrative or expert review; evidence still limited PubMed 36966972 DOI 10.1016/j.pharmthera.2023.108394
  10. 10
    The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. narrative or expert review; evidence still limited PubMed 21418147 DOI 10.1111/j.1748-1716.2011.02280.x
  11. 11
    2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice. animal study; mechanism-focused research PubMed 36125319 DOI 10.1111/acer.14949
  12. 12
    Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. animal study; mechanism-focused research PubMed 24768821 DOI 10.1016/j.exger.2014.04.008
See all 14 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. The Endocannabinoid System and its Modulation by Phytocannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 26271952
  2. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. narrative or expert review; evidence still limited / 1 linked research note PubMed 21418147
  3. Cannabinergic ligands. narrative or expert review; evidence still limited / 1 linked research note PubMed 12505686
  4. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. narrative or expert review; evidence still limited / 1 linked research note PubMed 16678907
  5. Endocannabinoid overload. narrative or expert review; evidence still limited / 1 linked research note PubMed 20952498
  6. Endocannabinoid hydrolases. narrative or expert review; evidence still limited / 1 linked research note PubMed 12432941
  7. Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. animal study; mechanism-focused research / 1 linked research note PubMed 39612328
  8. Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. animal study; mechanism-focused research / 1 linked research note PubMed 24768821
  9. Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. narrative or expert review; evidence still limited / 1 linked research note PubMed 36966972
  10. 2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice. animal study; mechanism-focused research / 1 linked research note PubMed 36125319
  11. The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. animal study; mechanism-focused research / 1 linked research note PubMed 33450278
  12. Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b. mechanism-focused research / 1 linked research note PubMed 36481187
  13. Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 24676249
  14. A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence. animal study; preclinical research / 1 linked research note PubMed 38052772